Sagimet Biosciences suspends and terminates ATM prospectus supplement for Series A common stock effective Sept. 30
SGMT•Sagimet Biosciences suspended and terminated its ATM prospectus supplement for Series A common stock effective Sept. 30, a SEC filing showed.
1. ATM prospectus supplement
Sagimet Biosciences suspended and terminated its ATM prospectus supplement for Series A common stock effective Sept. 30, a SEC filing showed.
